Pathogenetic Justification of the Use of 5-Alpha Reductase Inhibitors in the Treatment of Benign Prostatic Hyperplasia

The document reviewed the use of 5-alpha reductase inhibitors (5-ARI), specifically finasteride and dutasteride, in treating benign prostatic hyperplasia (BPH). It analyzed 36 sources, including prospective studies and randomized clinical trials, to evaluate the clinical and side effects of 5-ARI, their effectiveness, and reasons for inefficiency. The review found that while 5-ARI provided a moderate positive effect, they did not completely cure BPH. Known side effects suggested additional mechanisms beyond enzyme inhibition, necessitating further research. The lack of standardized effectiveness indicators and the inability to classify the disease's pathophysiological diversity were noted as challenges. The study concluded that further research is needed to understand the pancreatic tissue composition and disease pathogenesis to improve drug therapy outcomes and develop personalized treatments.